2024 saw the completion of several cellular-resolution brain maps, including the entire fly brain and a comprehensive connections map of a cubic centimeter of human brain. 2025 began with the addition of another important map. In the Jan. 1, 2025, issue of Nature, researchers from the Allen Institute presented a map of areas and cell types where aging most affected the mouse brain.
About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc. buyout in May 2024, with Vertex Pharmaceuticals Inc. seeking next-generation approaches for hemoglobinopathies.
After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that targets TDP-43, a protein directly linked to amyotrophic lateral sclerosis (ALS) pathology.
Yuhan Corp. has described pyrimidine/pyridine derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Scientists at Beigene Ltd. and Beigene Switzerland GmbH have divulged serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of inflammatory and autoimmune diseases.
Interline Therapeutics Inc. has synthesized receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
Atai Life Sciences has identified monoamine transporter modulators reported to be useful for the treatment of post-traumatic stress, eating disorders and obsessive-compulsive disorder.
Nimbus Therapeutics LLC has disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of alopecia, muscle atrophy and more.
RSS
